About Advanced Oncotherapy
AVO is a provider of internationally endorsed technology for advanced radiotherapy systems that are available to treat common and rare cancers.
Around the world today, more than 60% of cancer patients receive radiotherapy treatment as part of their cancer care. Radiation is damaging: when radiotherapy harms healthy tissue it can cause short- and long-term complications that are well documented in the literature. The continued challenge is to deliver adequate amounts of radiation to the tumour while sparing healthy tissue and vital organs like the heart, lungs, spinal cord, liver, bladder and kidneys.
AVO seeks to develop the technology and techniques to maximise the destructive effect of radiotherapy on the tumour while keeping healthy tissue healthy. AVO is a leader in affordable and accessible proton beam therapy along with other technologies such SD-IORT. AVO's focus is to develop advanced, cost effective and patient-friendly radiotherapy treatments which are clinically superior to those currently available.
Affordable advanced radiotherapy
Currently, the cost and size of proton therapy machines and the necessary edifices to house them explain why there are only 32 centres in the world. AVO's LIGHT equipment - the next generation for proton beam therapy, has a patented technology that eliminates that does not require a cyclotron or a synchrotron which each can weigh in excess of 200 tons.
The team‘s aim is to dramatically reduce the cost of delivering enhanced radiotherapy in the clinical setting. Thus, AVO makes radiotherapy more accessible to more patients with lower side effects and better outcomes.
In late September 2013, AVO completed its acquisition of ADAM S.A., a spin-off company from the European Organization for Nuclear Research (CERN), based in Geneva. This means that AVO is now the world-leader in providing 3-room proton beam therapy treatment centres in a rapidly growing market. Less than a month later, AVO had already set up agreements with ADAM for eight new LIGHT systems, which will be sent to treatment centres in the USA and the UK. The first of these will be ready in 2017.
AVO is also the market leader in the UK and Ireland in providing a fully managed radiotherapy service to the NHS and private sector to treat early stage breast cancer in one dose in one day.
AVO is an AIM-listed company registered and operating in England with an R&D facility located on the campus of CERN, Geneva, Switzerland